The Globe and Mail reports in its Friday, Jan. 26, edition that Scotia Capital analyst Michael Doumet has reaffirmed his "sector outperform" recommendation for ATS. The Globe's David Leeder writes in the Eye On Equities column that Mr. Doumet gave his share target a $3 boost to $64. Analysts on average target the shares at $66. Mr. Doumet says in a note: "We are ahead of consensus for 3QF24 -- and also expect upside to 4QF24 (i.e., we expect ATS's 4QF24 revenue guidance [provided with 3Q results] will also be a positive surprise). In essence, what we expect in the next two quarters is the 'best' from both transportation and life sciences: Transportation sales should approach their near-term top (as revenue burn with its large customer reaches a high) and life sciences sales should rise from higher auto-injector contributions. Similar to last quarter, we think the risk is to the backlog, which we expect to moderate given the high revenue burn. ATS trades at 13.5 times on our F25E -- expanding from 10 times following its 2QF24 earnings release -- and now trades closer to its three-year average. Since early November, 10-year rates have eased and the probability of an economic soft landing has increased."